BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3780828)

  • 1. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
    Breithaupt B; Tittel M
    Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
    Rüffer C; Zorn G; Henkel E; Mitzkat HJ
    Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Mertz DP; Eichhorn R
    Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
    Mertz DP; Borner K
    Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
    Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
    Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
    Gikalov I; Radivojevich F; Schiemann O; Fenner H
    Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
    Walter-Sack I; Gröbner W; Zöllner N
    Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
    Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
    Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained reductions in oxipurinol renal clearance during a restricted diet.
    Park GD; Berlinger WG; Spector R; Kitt TM; Tsalikian E
    Clin Pharmacol Ther; 1987 Jun; 41(6):616-21. PubMed ID: 3581647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
    Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
    Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
    Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic interaction between the active metabolite of allopurinol and benzbromarone].
    Farinotti R; Fredj G; Clavel JP; Colin JN; Nebout T
    Presse Med; 1986 Mar; 15(12):579. PubMed ID: 2939409
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of purine catabolism by benzbromarone in isolated rat liver cells. Comparison with allopurinol and probenecid.
    Rodilla F; Sanchez-Beltran MJ; Izquierdo R; Gomez-Ruiz MD; Cabo J
    Biochem Pharmacol; 1988 Oct; 37(19):3561-3. PubMed ID: 3178870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
    Saji M
    Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
    Yu TF
    J Rheumatol; 1976 Sep; 3(3):305-12. PubMed ID: 978666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
    Turnheim K; Krivanek P; Oberbauer R
    Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a thiazide-allopurinol drug interaction.
    Hande KR
    Am J Med Sci; 1986 Oct; 292(4):213-6. PubMed ID: 3752167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry.
    Lartigue-Mattei C; Chabard JL; Ristori JM; Bussiere JL; Bargnoux H; Petit J; Berger JA
    Fundam Clin Pharmacol; 1991; 5(7):621-33. PubMed ID: 1778540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
    Löffler W; Gröbner W; Zöllner N
    Arzneimittelforschung; 1983; 33(12):1687-91. PubMed ID: 6686776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.